Published 1 day ago • loading... • Updated 24 hours ago
BioSyent Declares Fourth Quarter 2026 Dividend
The quarterly payout matches the previous quarter and remains an eligible dividend for Canadian tax purposes, the company said.
On Tuesday, BioSyent Inc. President and CEO René Goehrum announced in Mississauga, Ontario, that the Board of Directors declared a quarterly dividend of $0.055 per common share, payable December 15, 2026.
BioSyent's recent performance includes $7.8 million in sales from the Oral Health segment during Q3 2026, following the March 1, 2026 acquisition of Oral Science Inc.
Strengthening its financial position, the company repaid $2 million in acquisition debt on October 1, 2026, while deploying $1.7 million in share buybacks and $0.6 million in dividends during Q3.
Goehrum noted the firm maintains a strong cash position to "hedge against future risks," supported by $6.0 million in combined operating cash flows during the third quarter.
Investment continues into 2027, with the company preparing to launch the pharmaceutical product Thyconvi in Canada during the first quarter of 2027.